Our investigation, which includes clinical correlations, experimental models, and in vivo validations, provides a comprehensive understanding of the complex function of CSMD1 in glioma progression and illuminates its potential as a therapeutic target and prognostic marker. This evidence concerns the gene CSMD1 and central nervous system cancer.